TABLE 2.
Neoadjuvant Chemotherapy Backbone
| Trial | Phase | Treatment Arms | Survival | n | pCR, % |
|---|---|---|---|---|---|
| Single-agent docetaxel | |||||
| NeoSphere | II | TH | 5-year DFS, 81% | 107 | 29 |
| THP | 5-year DFS, 84% | 107 | 46 | ||
| TP | 5-year DFS, 75% | 96 | 24 | ||
| HP | 5-year DFS, 80% | 107 | 17 | ||
| Anthracycline → docetaxel v docetaxel/carboplatin | |||||
| TRYPHAENA | II | FECHP → THP | 3-year OS, 94% | 73 | 62 |
| FEC → THP | 3-year OS, 94% | 75 | 57 | ||
| TCHP | 3-year OS, 93% | 77 | 66 | ||
| Anthracycline → paclitaxel v paclitaxel/carboplatin | |||||
| TRAIN-2 | III | FEC × 3 → wTCHP × 6 | 3-year OS, 98% | 211 | 67 |
| wTCHP × 9 | 3 year OS, 98% | 206 | 68 | ||
| Anthracycline → paclitaxel v docetaxel | |||||
| BERENICE | II | ddAC → wTHP | 5-year OS, 96% | 199 | 62 |
| FEC → THP | 5-year OS, 94% | 201 | 61 | ||
| Single-agent paclitaxel or nab-paclitaxel | |||||
| GeparSepto | III | wT + HP → EC + HP | 4-year iDFS, 89% | 199 | 54 |
| NabTHP → EC + HP | 197 | 62 | |||
| ADAPT HER2+/HR– | II | HP | 5-year OS, 94% | 92 | 34 |
| THP | 5-year OS, 98% | 42 | 90 |
NOTE. This table shows the regimens given before surgery (primary end point was pCR). Postoperative treatments varied across trials. The taxane used is shown in bold.
Abbreviations: C, carboplatin; ddAC, dose-dense doxorubicin and cyclophosphamide; DFS, disease-free survival rate; FEC, fluorouracil, epirubicin, and cyclophosphamide; H, trastuzumab; HER2, human epidermal growth factor receptor 2; iDFS, invasive DFS rate; NabT, nab-paclitaxel; OS, overall survival rate; pCR, pathological complete response rate; P, pertuzumab; T, docetaxel; wT, paclitaxel.